Healthcare Experience


Our Healthcare experience includes 812 clients, with 73 partnered brands and 759 USAN/INN names. Below is our extensive portfolio, feel free to filter by clients, brands, category or USAN/INN Names.   ||  Click Here for Consumer/B2B Experience



CLIENTS BRANDS CATEGORY
OPEXA THERAPEUTICS ABILI-T Clinical Trial Name
OTSUKA PHARMACEUTICAL ABILIFY MAINTENA * Neurology
OBI PHARMA adagloxad simolenin Immunology
OTTOBOCK AGILIUM FREESTEP Medical Device
OTICON ALTA Medical Device
ORION PHARMA ARAMIS (ANDROGEN RECEPTOR INHIBITING AGENT FOR METASTATIC-FREE SURVIVAL Clinical Trial Name
OTSUKA PHARMACEUTICAL brexpiprazole Neurology
ONCOMED brontictuzumab Oncology
ONO ceralifimod immunology
Oscotec cevidoplenib Immunology
OBAGI MEDICAL CLENZIDERM M.D. Dermatology
ORION PHARMA COMTAN * Neurology
OREXIGEN THERAPEUTICS CONTRAVE * Obesity
OCTAPHARMA CUTAQUIG Immunology
OLATEC dapansutrile Pain & Inflammation
OTSUKA PHARMACEUTICAL DELTYBA Antibiotic
ONCOMED demcizumab Oncology
ORTHO-MCNEIL PHARMACEUTICAL DURAGESIC Pain & Inflammation
ONCOTHERAPY SCIENCE elpamotide Oncology
Onxeo etidaligide Oncology
OncoMed etigilimab Oncology
OCTAPHARMA AB FIBRYNA * Hematology
OXIGENE fosbretabulin Oncology
OXIGENE fosbretabulin disodium Oncology
OXIGENE fosbretabulin tromethamine Oncology
OSI PHARMACEUTICALS GALACCTIC Clinical Trial Name
OPEXA THERAPEUTICS imilecleucel-t Immunology
OPEXA THERAPEUTICS IMMPATH Technology Name
ONCOMED ipafricept Oncology
OTSUKA PHARMACEUTICAL JINARC * Nephrology
OTSUKA PHARMACEUTICAL JYNARQUE * Nephrology
ONCOTHERAPY SCIENCE latromotide Oncology
OSI PHARMACEUTICALS linsitinib Oncology
ONCOPEPTIDES melphalan flufenamide Oncology
OTSUKA PHARMACEUTICAL MIKELUNA Ophthalmology
ONCOMED navicixizumab Oncology
ONCOMED navicixizumab Oncology
ORION PHARMA neluxicapone Neurology
OTICON NERA Medical Device
OCTAPHARMA AB NUWIQ * Hematology
OTSUKA PHARMACEUTICAL ORALTAG * Medical Device
ORTHOSENSOR ORTHOSENSOR Corporate Identity
OSMOTICA PHARMACEUTICAL OSMOLEX ER Neurology
ONCOLOGY THERAPEUTICS NETWORK OTN - ONCOLOGY THERAPEUTICS NETWORK Corporate Identity
ORTHO-MCNEIL PHARMACEUTICAL PANCREAZE Gastrointestinal
OCTAPHARMA AB PANZYGA * Immunology
ONCOTHERAPY SCIENCE pradimotide Oncology
OPKO HEALTH RAYALDEE * Nephrology
ORTHO-MCNEIL PHARMACEUTICAL RAZADYNE Neurology
ORTHO-MCNEIL PHARMACEUTICAL RAZADYNE ER Neurology
ORTHO DERMATOLOGICS RETIN-A MICRO PUMP Medical Device
OTSUKA PHARMACEUTICAL REXULTI * Neurology
ONCOMED rosmantuzumab Oncology
OWP PHARMACEUTICALS ROWEEPRA Neurology
OVATION PHARMACEUTICALS SABRIL * Neurology
OCTAPHARMA AB satoreotide Oncology
OCTREOPHARM satoreotide trizoxetan Oncology
OBAGI MEDICAL SOLUCLENZ Dermatology
OSSUR SYMBIONIC LEG Medical Device
ONCOTHERAPYSCIENCE tabituximab Oncology
ONCOTHERAPYSCIENCE tabituximab barzuxetan Oncology
OSI PHARMACEUTICALS TARCEVA * Oncology
ONCOMED tarextumab Oncology
ORION PHARMA tasipimidine Animal Health
OncoSec tavokinogene telseplasmid Oncology
OTSUKA PHARMACEUTICAL tolvaptan Nephrology
ORTHO-MCNEIL PHARMACEUTICAL TOPAMAX Neurology
ONCOMED vantictumab Oncology
OSMOTICA PHARMACEUTICAL VENALTA - Product Identity
ORTHOSENSOR VERASENSE Medical Device
OCTAPHARMA AB VIHUMA Hematology
OPTINOSE XHANCE * Respiratory
OREXO AB ZUBSOLV * Neurology
OCERA THERAPEUTICS ZYSA Gastrointestinal


* Denotes a comprehensive report of the safety regulatory research prepared by BI/DSI for submission of this name candidate to FDA, EMA, Health Canada, JMHLW, ANVISA, ROSZDRAVNADZOR, CDSCO, CFDA, KOREA MFDS, and/or other Regulatory Agencies.

Back to top